Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trial.
Cornelis Cees J TackStephan JacobCyrus DesouzaStephen C BainJohn B BuseMichael A NauckJohn R PetrieNeil R PoulterRichard E PratleyHelen Vanya B K StegmannHeidrun Bosch-TrabergElena StartsevaBernard Zinmannull nullPublished in: Diabetes, obesity & metabolism (2019)
In patients on insulin, liraglutide improved glycaemic control, weight and need for insulin versus placebo, for at least 36 months with no increased risk of severe hypoglycaemia, while maintaining CV safety/efficacy, supporting the combination of liraglutide and insulin for management of type 2 diabetes.
Keyphrases
- type diabetes
- glycemic control
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- ejection fraction
- body mass index
- phase iii
- study protocol
- clinical trial
- physical activity
- prognostic factors
- insulin resistance
- randomized controlled trial
- peritoneal dialysis
- weight gain
- mesenchymal stem cells
- open label
- skeletal muscle
- body weight
- double blind
- placebo controlled